OCEANIC-AF (Completed)

Multicenter, randomized, active comparator-controlled, double-blind, double-dummy, parallel group phase III study of the oral FXIa inhibitor BAY 2433334 for the prevention of stroke or systemic embolism in patients with atrial fibrillation